Travere Therapeutics Provides Corporate Update and 2024 Outlook

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) —  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales from continuing operations for the fourth quarter of 2023 to be approximately $40 million .

View Full Press Release